IRIS Accounts Production v25.4.0.155 08999306 Board of Directors 1.9.24 31.8.25 31.8.25 0 0 false true false false false true false Ordinary 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 08999306 2024-08-31 08999306 2025-08-31 08999306 2024-09-01 2025-08-31 08999306 2023-08-31 08999306 2023-09-01 2024-08-31 08999306 2024-08-31 08999306 ns15:EnglandWales 2024-09-01 2025-08-31 08999306 ns14:PoundSterling 2024-09-01 2025-08-31 08999306 ns10:Director1 2024-09-01 2025-08-31 08999306 ns10:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 08999306 ns10:SmallEntities 2024-09-01 2025-08-31 08999306 ns10:AuditExempt-NoAccountantsReport 2024-09-01 2025-08-31 08999306 ns10:SmallCompaniesRegimeForDirectorsReport 2024-09-01 2025-08-31 08999306 ns10:SmallCompaniesRegimeForAccounts 2024-09-01 2025-08-31 08999306 ns10:FullAccounts 2024-09-01 2025-08-31 08999306 1 2024-09-01 2025-08-31 08999306 ns10:OrdinaryShareClass1 2024-09-01 2025-08-31 08999306 ns10:Director2 2024-09-01 2025-08-31 08999306 ns10:Director3 2024-09-01 2025-08-31 08999306 ns10:CompanySecretary1 2024-09-01 2025-08-31 08999306 ns10:RegisteredOffice 2024-09-01 2025-08-31 08999306 ns5:CurrentFinancialInstruments 2025-08-31 08999306 ns5:CurrentFinancialInstruments 2024-08-31 08999306 ns5:ShareCapital 2025-08-31 08999306 ns5:ShareCapital 2024-08-31 08999306 ns5:SharePremium 2025-08-31 08999306 ns5:SharePremium 2024-08-31 08999306 ns5:RetainedEarningsAccumulatedLosses 2025-08-31 08999306 ns5:RetainedEarningsAccumulatedLosses 2024-08-31 08999306 ns5:IntangibleAssetsOtherThanGoodwill 2024-09-01 2025-08-31 08999306 ns5:IntangibleAssetsOtherThanGoodwill 2024-08-31 08999306 ns5:IntangibleAssetsOtherThanGoodwill 2025-08-31 08999306 ns5:IntangibleAssetsOtherThanGoodwill 2024-08-31 08999306 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-08-31 08999306 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-08-31 08999306 ns10:OrdinaryShareClass1 2025-08-31

REGISTERED NUMBER: 08999306 (England and Wales)

| UNAUDITED FINANCIAL STATEMENTS |

| FOR THE YEAR ENDED 31 AUGUST 2025 |

| FOR |

| GENE SOLUTIONS (UK) LTD |

GENE SOLUTIONS (UK) LTD (REGISTERED NUMBER: 08999306)

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 AUGUST 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 4 |

GENE SOLUTIONS (UK) LTD

COMPANY INFORMATION

FOR THE YEAR ENDED 31 AUGUST 2025

| DIRECTORS: | E P Connell

| J E Oury

| D B Patteson

| SECRETARY: | A C Oury

| REGISTERED OFFICE: | 10 John Street

| London

| WC1N 2EB

| REGISTERED NUMBER: | 08999306 (England and Wales)

| ACCOUNTANTS: | Oury Clark Chartered Accountants

| Herschel House

| 58 Herschel Street

| Slough

| Berkshire

| SL1 1PG

GENE SOLUTIONS (UK) LTD (REGISTERED NUMBER: 08999306)

BALANCE SHEET

31 AUGUST 2025

| 31.8.25 | 31.8.24 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Intangible assets | 4 | 1 |  | 1 |  |

CURRENT ASSETS

Debtors | 5 | 1,710 |  | 115 |  |

Cash at bank | 43,775 |  | 44,540 |  |

45,485 |  | 44,655 |  |

CREDITORS

Amounts falling due within one year | 6 | 4,561,049 |  | 4,392,738 |  |

NET CURRENT LIABILITIES | (4,515,564 | ) | (4,348,083 | ) |

TOTAL ASSETS LESS CURRENT LIABILITIES | (4,515,563 | ) | (4,348,082 | ) |

CAPITAL AND RESERVES

Called up share capital | 7 | 903 |  | 903 |  |

Share premium | 99,870 |  | 99,870 |  |

Retained earnings | (4,616,336 | ) | (4,448,855 | ) |

SHAREHOLDERS' FUNDS | (4,515,563 | ) | (4,348,082 | ) |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 August 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 August 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

GENE SOLUTIONS (UK) LTD (REGISTERED NUMBER: 08999306)

BALANCE SHEET - continued

31 AUGUST 2025

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 6 March 2026 and were signed on its behalf by:

E P Connell - Director

GENE SOLUTIONS (UK) LTD (REGISTERED NUMBER: 08999306)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 AUGUST 2025

1. | STATUTORY INFORMATION

| Gene Solutions (UK) Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| After making enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence and meet its liabilities as they fall due for the foreseeable future, being a period of at least twelve months from the date these financial statements were approved. Accordingly they continue to adopt the going concern basis in preparing the financial statements.

| Intangible assets

| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

| Amortisation and impairment begins when the intangible assets are put into use.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Research and development

| Expenditure on research and development is written off in the year in which it is incurred.

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

GENE SOLUTIONS (UK) LTD (REGISTERED NUMBER: 08999306)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 AUGUST 2025

2. | ACCOUNTING POLICIES - continued

| Basic financial instruments

| Basic Financial Instruments as covered by Section 11 of FRS 102 (Section 1A) are measured at amortised cost. The company does not have any Other Financial Instrument as covered by Section 12 of FRS 102 (Section 1A).

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was NIL (2024 - NIL).

4. | INTANGIBLE FIXED ASSETS

| Other

| intangible

| assets

£ |

| COST

| At 1 September 2024

| and 31 August 2025 | 1 |  |

| NET BOOK VALUE

| At 31 August 2025 | 1 |  |

| At 31 August 2024 | 1 |  |

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 31.8.25 |  | 31.8.24

£ | £ |

| Other debtors | 1,710 |  | 115 |  |

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 31.8.25 |  | 31.8.24

£ | £ |

| Amounts owed to group undertakings | 4,559,049 |  | 4,386,738 |  |

| Other creditors & accruals | 2,000 |  | 6,000 |  |

4,561,049 |  | 4,392,738 |  |

7. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 31.8.25 |  | 31.8.24

| value: | £ | £ |

| 903 | Ordinary | £1 | 903 |  | 903 |  |

8. | ULTIMATE PARENT COMPANY

| Gene Solutions LLC (incorporated in USA) is regarded by the directors as being the company's ultimate parent company.